Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data

• Published in: Future oncology (London, England) England), 2022-06, Vol.18 (17), p.2063-2074
• Main Authors: Tremblay, Gabriel, Groff, Michael, Iadeluca, Laura, Daniele, Patrick, Wilner, Keith, Wiltshire, Robin, Bartolome, Lauren, Usari, Tiziana, Cappelleri, Joseph C, Camidge, D Ross
• Format: Article
• Language: English
• Subjects: Benzamides - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Clinical Trials as Topic; Crizotinib - therapeutic use; Humans; Indazoles - therapeutic use; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - therapeutic use; Proto-Oncogene Proteins - genetics; Treatment Outcome
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2021-1102

To compare clinical trial results for crizotinib and entrectinib in -positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Crizotinib and entrectinib have comparable efficacy in -positive non-small-cell lung cancer.